Alimera Sciences, created in June 2003, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. We are presently focused on diseases affecting the back of the eye, or retina, because we believe these diseases are not well treated with current therapies and as the world’s population continues to age, more and more people will be afflicted by these diseases. Alimera has recently announced positive results from the month 24 readout of the FAME Study for the use of Iluvien® in the treatment of diabetic macular edema (DME) and plans to file a New Drug Application (NDA) in the United States in the second quarter of 2010 followed by registration filings in certain European countries and Canada.

Recent Releases

Jul 29, 2010
Alimera Sciences to Hold Conference Call to Discuss Second Quarter 2010 Financial Results

Jul 8, 2010
Alimera Sciences Submits Iluvien(R) MAA for the Treatment of Diabetic Macular Edema

View all releases »

Events & Presentations

Aug 12, 2010 at 4:30 PM ET
2Q 2010 Earnings Conference Call

View all events & presentations »